Xiaojin Shi

TL;DR: The IMPRESS trial as discussed by the authors evaluated the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefinib.

TL;DR: Final OS data from IMPRESS are supportive of earlier PFS results and are sufficient to warn physicians against the continuation of treatment with first-generation EGFR tyrosine kinase inhibitors beyond radiologic disease progression when chemotherapy is initiated.

TL;DR: The IMPRESS study is the first and only randomised Phase III study to confirm continuation of gefitinib in addition to cis/pem would be of no clinical benefit for pts with acquired resistance to gef itinib; thus the standard of care should remain doublet chemotherapy alone.

TL;DR: In this article , the authors evaluated tremelimumab plus durvalumab and chemotherapy (T + D + CT) versus chemotherapy alone (CT) in first-line metastatic non-small-cell lung cancer (mNSCLC).